Abstract: The invention relates to a solution-based assay for identifying RNA binding compounds, based on competition. The assay comprises a reporter molecule carrying a fluorescent or chromogenic group that can form a one-to-one complex with an RNA target molecule carrying a second fluorescent or chromogenic group in such a way that the two groups are in sufficient proximity for fluorescence resonance energy transfer and/or quenching to take place. Addition of a compound-to-be-tested prevents formation of the complex and thereby increases the fluorescence of the RNA target and/or reporter molecules relative to the signal obtained in the absence of the test compound. The invention also provides for quantitative screening methods and kits are also included.
Type:
Grant
Filed:
June 3, 1999
Date of Patent:
June 3, 2003
Assignee:
Ribotargets, Ltd.
Inventors:
Jonathan Karn, Catherine Denise Prescott
Abstract: The invention relates to an isolated nucleic acid comprising two operatively linked binding sites for HIV Rev protein, the sites comprising a nucleation motif and an oligomerization motif, wherein the nucleic acid binds Rev protein monomers with a higher degree of co-operativity than wild-type RRE.
Type:
Grant
Filed:
April 15, 1997
Date of Patent:
May 1, 2001
Assignee:
Ribotargets, Ltd.
Inventors:
Jonathan Karn, Rodney Warren Zemmel, Peter Jonathan Gasking Butler, Roger K. Craig, Alistair Simpson Irvine
Abstract: A synthetic molecule comprises at least one oligonucleotide comprising an RNA binding sequence or sequences corresponding to the site bound by the HIV protein rev and capable of binding ot rev within cells. The binding sequence or sequences, by binding with rev within cells, can act to cause inhibition of growth of any HIV present in the cells, and so has potential therapeutic use in treatment of patients infected with HIV. The invention also provides an assay for identifying that inhibit rev binding.
Type:
Grant
Filed:
September 15, 1997
Date of Patent:
November 28, 2000
Assignee:
Ribotargets, Ltd.
Inventors:
Jonathan Karn, Michael John Gait, Shaun Heaphy, Colin Dingwall
Abstract: A synthetic molecule comprises at least one oligonucleotide, comprising and RNA binding sequence or sequences corresponding to the site bound by the HIV protein tat and capable of binding to tat within cells. The binding sequence or sequences, by binding tat within cells, can act to cause inhibition of growth of any HIV present in the cells, and so has potential therapeutic use in treatment of patients affected with HIV. The invention also provides an assay for identifying compounds that inhibit tat binding.
Type:
Grant
Filed:
May 22, 1998
Date of Patent:
September 5, 2000
Assignee:
RiboTargets, Ltd.
Inventors:
Jonathan Karn, Michael J. Gait, Shaun Heaphy, Colin Dingwall